Analyst Price Targets — DRUG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 13, 2026 2:15 pm | — | Robert W. Baird | $126.00 | $78.71 | TheFly | Bright Minds price target lowered to $126 from $142 at Baird |
| January 7, 2026 12:56 pm | — | Robert W. Baird | $142.00 | $81.70 | TheFly | Bright Minds price target raised to $142 from $82 at Baird |
| January 7, 2026 11:42 am | — | BTIG | $147.00 | $93.21 | TheFly | Bright Minds price target raised to $147 from $72 at BTIG |
| May 7, 2025 8:45 am | Rudy Li | Chardan Capital | $80.00 | $29.02 | TheFly | Bright Minds initiated with a Buy at Chardan |
| January 10, 2025 11:09 am | Patrick Trucchio | H.C. Wainwright | $85.00 | $38.89 | TheFly | Bright Minds Biosciences initiated with a Buy at H.C. Wainwright |
Latest News for DRUG
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DRUG.
U.S. House Trading
No House trades found for DRUG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.